Advertisement

 

 

Laboratory Testing of a Cohort of Commercially Insured Users of HIV Preexposure Prophylaxis in the United States, 2011-2015.

Laboratory Testing of a Cohort of Commercially Insured Users of HIV Preexposure Prophylaxis in the United States, 2011-2015.
Author Information (click to view)

Huang YA, Tao G, Samandari T, Hoover KW,


Huang YA, Tao G, Samandari T, Hoover KW, (click to view)

Huang YA, Tao G, Samandari T, Hoover KW,

Advertisement

The Journal of infectious diseases 2017 11 14() doi 10.1093/infdis/jix595

Abstract

To ensure the health and safety of persons taking antiretroviral medication for HIV preexposure prophylaxis (PrEP), CDC guidelines recommend initial and follow-up laboratory testing. We assessed the rates of recommended testing using a commercial insurance claims database. Before taking PrEP, 45% of users were tested for HIV, 31% for creatinine, 55% for syphilis, 43% for chlamydia/gonorrhea, and 38% for hepatitis B. By 6 months after PrEP initiation, 38% were tested for HIV, 37% for creatinine, 49% for syphilis, and 39% for chlamydia/gonorrhea. Although laboratory testing was less frequent than recommended, testing rates increased over the study period.

Submit a Comment

Your email address will not be published. Required fields are marked *

six − 2 =

[ HIDE/SHOW ]